Related Experiment Video

Updated: Jun 25, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K

PAQR4 oncogene: a novel target for cancer therapy

Dipti Patil1, Swapnil Raut1, Mitesh Joshi2

  • 1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (West), Mumbai, 400056, India.

Medical Oncology (Northwood, London, England)
|May 20, 2024
PubMed

Insights

Drug resistance remains a major challenge in cancer treatment. This review highlights Progestin and AdipoQ Receptor Family Member 4 (PAQR4) as a potential target for overcoming chemoresistance and improving cancer therapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cancer drug resistance significantly hinders treatment efficacy, leading to high morbidity and mortality.
  • Understanding the mechanisms of drug resistance is crucial for developing effective cancer therapies.
  • PAQR4 (Progestin and AdipoQ Receptor Family Member 4) is a novel protein implicated in various cancers.

Purpose of the Study:

  • To review the multifaceted roles of PAQR4 in cancer pathogenesis.
  • To explore PAQR4's influence on tumor immunity, carcinogenesis, and chemoresistance.
  • To identify PAQR4 as a potential therapeutic target in malignancies.

Main Methods:

  • Literature review of existing studies on PAQR4.
  • Analysis of PAQR4's involvement in cancer-related signaling pathways.
  • Synthesis of current knowledge on PAQR4's impact on drug resistance.

Main Results:

  • PAQR4 influences multiple proteins that regulate gene expression and contribute to chemoresistance.
  • PAQR4 plays a role in tumor immunity and the development of cancer.
  • This review is the first to comprehensively discuss PAQR4 in cancer pathogenesis.

Conclusions:

  • PAQR4 is a significant factor in cancer development and chemoresistance.
  • Targeting PAQR4 presents a promising strategy for overcoming drug resistance in cancer patients.
  • Further research into PAQR4's mechanisms could lead to novel cancer treatments.
Keywords:
CancersPAQR4Therapeutic targetTumor immunitymiRNA

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

295

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K